Figure 1: Luteolin overcomes the resistance of FasL-mediated cell death in HepG2 cells. (A) HepG2 cells were treated with various concentrations of FasL for 24h. (B) HepG2 cells were pretreated with indicated concentrations of luteolin for 2h, followed by treatment with 60ng/ml FasL for another 22h. Cells viability was determined by MTT assay as described in Material and Methods. Cells viability without treatment was taken as 100%. Data are means ± S.D. of three independent experiments.